BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:Contr. talk - Study of anti-cancer effects of TTA-A2 and paclitaxe
 l due to antagonistic interactions with T-type calcium channels
DTSTART;VALUE=DATE-TIME:20210525T124000Z
DTEND;VALUE=DATE-TIME:20210525T130000Z
DTSTAMP;VALUE=DATE-TIME:20260722T100015Z
UID:indico-contribution-1132@lindico453.srv.lu.se
DESCRIPTION:Speakers: Vikram Dalal (Washington University in St. Louis)\nS
 tudies have shown that in cancer cells\, there is an increased T-type calc
 ium channel (TTCC) expression compared to healthy cells. Therefore\, the s
 tudies targeting TTCC for cancer therapy\nhave shown many positive outcome
 s. Here\, we have used TTA-A2- a potent TTCC inhibitor as a test drug\, an
 d paclitaxel (PTX)- a tubule-binding anti-cancer agent as a positive contr
 ol. Blocking\nTTCC has shown to overcome resistance in cancer cells toward
 s anti-cancer drugs by reducing calcium influx\, and some studies have sho
 wn that PTX treatment also reduces the intracellular calcium signaling in 
 cells. So\, there is a possibility that PTX might be interacting with calc
 ium channels. Since\, drug-drug interaction can cause severe side-effects\
 , or alter the actions of each other\; we aim to study the interactions am
 ong TTA-A2\, PTX\, and TTCC. Therefore\, in this study we have analyzed th
 e binding of of TTA-A2 and PTX with TTCC. Our results showed that both the
  drugs\, TTA-A2 and PTX\, could interact at the same site of TTCC to form 
 a higher stable complex as compared to the TTCC-native. The result indicat
 ed that sequential treatment could help to overcome the antagonistic inter
 action between the two drugs.\n\nhttps://lindico453.srv.lu.se/event/219/co
 ntributions/1132/
LOCATION:
URL:https://lindico453.srv.lu.se/event/219/contributions/1132/
END:VEVENT
END:VCALENDAR